ClinicalTrials.gg
CompletedNCT01537042Updated Nov 3, 2014Results posted

A Sleep Laboratory Study to Investigate the Safety and Efficacy of the Rotigotine Skin Patch in Subjects With Restless Legs Syndrome and End-Stage Renal Disease Requiring Hemodialysis

A Phase 3 interventional study of Rotigotine and Placebo in Restless Legs Syndrome and End-Stage Renal Disease, sponsored by UCB BIOSCIENCES GmbH. Completed at 15 sites in 6 countries. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2014-11-03.

Sponsored by UCB BIOSCIENCES GmbH (part of UCB S.A.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
30
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies testing rotigotine in Restless Legs Syndrome — none open to participants now, none under way, none of them phase 3. rotigotine · Restless Legs Syndrome.

Enrollment
15th of 19
30 · median 130
Started
2012
with 2 others
Phase 3
10 of 19
none open now
Registered
13th of 19
by date
Lead sponsor
2 of 19
UCB BIOSCIENCES GmbH

Among the 19 studies testing rotigotine in Restless Legs Syndrome, this one is the 15th largest by enrollment, is one of 3 that started in 2012, is one of 10 in phase 3, and was the 13th registered.

Restless Legs Syndrome

259 studies on the registry are indexed under Restless Legs Syndrome; 38 are open to participants now.

Browse Restless Legs Syndrome studies →

Open to participants now

None of the 19 studies testing rotigotine in Restless Legs Syndrome is open now. The open studies under Restless Legs Syndrome, anywhere →

About rotigotine

rotigotine: first FDA approval 2007 (NEUPRO), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 25 Restless Legs Syndrome studies recruiting now, 10 (40%) set no upper age limit and 12 (48%) stop at 75 or younger; none take children under 18; 10 take healthy volunteers.

This study: 18 Years to 85 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 19 studies testing rotigotine in Restless Legs Syndrome as a file.
02

Study summary

This is a sleep laboratory study to evaluate the efficacy and safety of Rotigotine in subjects with Restless Legs Syndrome and End-Stage Renal Disease requiring hemodialysis.

The objectives are to demonstrate superiority of Rotigotine against Placebo as well as to investigate the effect of Rotigotine on quality of life and sleep.

03

Conditions studied

  • Restless Legs Syndrome
  • End-Stage Renal Disease

Keywords

  • Rotigotine
  • Neupro
  • Restless Legs Syndrome
  • RLS
  • End-Stage Renal Disease
04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • End-Stage Renal Disease (ESRD) requiring hemodialysis and regular dialysis schedule
  • Fulfillment of pre-defined criteria of hematology parameters
  • Diagnosis of Restless Legs (RLS) based on the 4 cardinal diagnostic clinical features according to the International Restless Legs Syndrome Study Group
  • Initial response to previous dopaminergic treatment for RLS, or has had no previous dopaminergic treatment (ie, de novo)
  • Score of ≥ 15 points on the IRLS (indicating moderate to severe RLS) at Baseline
  • Score of ≥ 11 points on the RLS-DI (Diagnostic Index) at Baseline
  • Score of ≥ 4 points on the Clinical Global Impressions (CGI) Item 1 assessment (indicating moderately ill) at Baseline
  • Scores ≥ 15 Periodic Limb Movements (PLMs) per hour on the Periodic Limb Movement Index (PLMI) based on Polysomnography (PSG) (recorded during the second night) as assessed by the investigator at Baseline

Exclusion criteria

Exclusion Criteria:

  • Polyneuropathy or Varicosis which cannot be clearly differentiated from RLS symptoms in the opinion of the investigator
  • Clinically relevant concomitant diseases, such as Attention Deficit Hyperactivity Disorder, Painful Legs, and Moving Toes
  • Other central nervous system diseases
  • Evidence of an impulse control disorder according to the modified Minnesota Impulsive Disorders Interview (mMIDI)
  • Lifetime history of suicide attempt (including an active attempt, interrupted attempt, or aborted attempt), or has suicidal ideation in the past 6 months as indicated by a positive response ('yes') to either Question 4 or Question 5 of the Columbia-Suicidality Severity Rating Scale (C-SSRS) at Screening (Visit 1) or Baseline (Visit 2)
  • Prior history of psychotic episodes
  • History of symptomatic (not asymptomatic) Orthostatic Hypotension
  • Clinically relevant Cardiovascular Disease
  • Clinically relevant Venous or Arterial Peripheral Vascular Disease
  • Malignant Neoplastic Disease requiring therapy within 12 months prior to Screening (Visit 1)
  • Treatment with any of the following drug classes: neuroleptics, norepinephrine and dopamine reuptake inhibitors (bupropion), gabapentin, budipine, dopamine antagonist antiemetics (except domperidone), opioids, monoamine oxidase (MAO) inhibitors, catechol-O-methyltransferase (COMT) inhibitors, or psychostimulants (eg, amphetamines)
  • Subject is pregnant, nursing, or is a woman of who is not surgically sterile, 2 years , or does not consistently use 2 combined effective methods of (including at least 1 barrier method), unless sexually abstinent
  • Previous treatment with dopamine agonists within a period of 14 days prior to Baseline (Visit 2), or L-dopa within 7 days prior to Baseline (Visit 2)
  • Medical history indicating intolerability to dopaminergic therapy (if pretreated) or has experienced Augmentation (Garcia-Borreguero and Williams, 2010) when previously treated with any dopaminergic agent
  • Subject has received previous treatment with Rotigotine
  • Known to any of the components of the study medication, such as a history of significant Skin Hypersensitivity to adhesives, known Hypersensitivity to other transdermal medications, or unresolved Contact Dermatitis
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
30 participants (actual)

Study arms

  • Experimental
    Rotigotine

    Rotigotine Transdermal Patch 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h.

    Drug: Rotigotine

  • Placebo comparator
    Placebo

    Transdermal patch matched according to patch size and appearance.

    Drug: Placebo

Interventions

  • Transdermal patch; Dose: 1 mg/24 h, 2 mg/24 h or 3 mg/24 h once daily depending on optimal dose; maximal dose is 3 mg/24 h. Subjects start with a Rotigotine dose of 1 mg/24 h for 1 week. The dose can be increased weekly during Up-Titration Period until either the optimal or the maximal dose of 3 mg/24 h has been reached. Subjects will maintain the optimal/maximal dose during the 2-week Maintenance Period. Following the Maintenance Period, subjects will be de-escalated from their optimal dose by decreasing the dose by 1 mg/24 h every other day during Taper Period until complete withdrawal.

    Also known as: Neupro

  • DrugPlacebo

    Transdermal patch; Patches matching to active treatment patches in size and appearance. Up to 3 weeks of Titration, 2 weeks of Maintenance, Up to 4 days of Taper Period.

06

What researchers measure

Primary outcomes

  1. Ratio From Baseline to the End of the 2-week Maintenance Period in Periodic Limb Movement Index (PLMI)

    The PLMI is defined as Periodic Limb Movements (PLMs)/ total time in bed in hours. PLMs are measured by Polysomnography (PSG). The reduction of the PLMI is reflected in terms of the ratio from Baseline to the end of the Maintenance Period and was calculated as \[PLMI at end of Maintenance Period (MP)\] / \[PLMI at Baseline\]. A PLMI Ratio \<1 indicates an improvement from Baseline to the end of the 2-week MP.

    Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period

Secondary outcomes

  1. Change From Baseline in the Periodic Limb Movements Index (PLMI) to the End of the Maintenance Period

    The PLMI is defined as Periodic Limb Movements (PLMs)/ total time in bed in hours. PLMs are measured by Polysomnography (PSG). A negative value in change from Baseline indicates an improvement from Baseline to the end of the Maintenance Period.

    Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period

  2. Change From Baseline in the International Restless Legs Syndrome Study Group Rating Scale (IRLS) Sum Score to the End of the Maintenance Period

    The IRLS is a subject based scale that consists of 10 items to evaluate the severity of major RLS symptoms and the impact of the disease on subjects' functioning in daytime activities. Each of the 10 items is measured on a scale that ranges from 0 (not present) to 4 (severe). A sum score between 0 (no RLS symptoms present at all) and 40 (maximum severity in all symptoms) across all 10 items will be calculated. A negative value in Change from Baseline indicates an improvement from Baseline in IRLS.

    Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period

  3. Change From Baseline in Clinical Global Impressions (CGI) Item 1 Score

    The CGI Item 1 score measures the severity of illness on a scale that ranges from 0 (Not assessed) to 7 (Among the most extremely ill).

    Time frame: Visit 2 (Baseline); Visit 6 (End of Maintence Period)

  4. Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 1 to the End of the Maintenance Period

    The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 1 measures satisfaction with sleep during the last seven nights on an 11-point scale that ranges between 0 (completely satisfied) to 10 (completely dissatisfied). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period

  5. Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 2 to the End of the Maintenance Period

    The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 2 measures the severity of RLS symptoms during the last 7 nights in the situation of falling asleep. This is measured on an 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period

  6. Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 3 to the End of the Maintenance Period

    The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 3 measures the severity of RLS symptoms during the last seven nights on an 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period

  7. Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 4 to the End of the Maintenance Period

    The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 4 measures the severity of RLS symptoms during the last seven days at rest on an 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period

  8. Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 5 to the End of the Maintenance Period

    The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 5 measures the severity of RLS symptoms during the last seven days engaged in activities on an 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period

  9. Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 6 to the End of the Maintenance Period

    The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 6 measures the severity of daytime tiredness/ sleepiness on an 11-point scale that ranges between 0 (not at all) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period

  10. Change From Baseline in the Periodic Limb Movement During Sleep Arousal Index (PLMSAI) to the End of the Maintenance Period

    The Periodic Limb Movement during Sleep Arousal Index (PLMSAI) reflects the influence of the PLM on subject's sleep. Arousal is defined as sudden change in the Electroencephalogram (EEG) activity and the index illustrates to what degree the PLMs contribute to arousal from sleep. A negative value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period

  11. Change From Baseline in Sleep Efficiency to the End of the Maintenance Period

    Sleep stages and time spent in each sleep stage are determined from Electroencephalogram (EEG) readings. Sleep stage data will be used to calculate sleep efficiency. Sleep efficiency will be presented as percentages. Sleep efficiency is the percentage of time in bed spent asleep. A postive value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period

  12. Change From Baseline in the Restless Legs-Quality of Life (RLS-QoL) Total Score to the End of the Maintenance Period

    The RLS-QoL is a disease-specific questionnaire to evaluate quality of life. It consists of 12 items. A total score will be calculated from all of the 12 items. The overall sum score can be from 0 (highest QoL) to 60 (lowest QoL). A negative value in Change from Baseline indicates an improvement from Baseline.

    Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period

  13. Change From Baseline in the Short-Form-36 (SF-36) Item Questionnaire Mental Component Summary (MCS) to the End of the Maintenance Period

    The SF-36 is a 36 item generic human research quality of life instrument that uses a recall period of 4 weeks. Items are grouped into 8 domains as follows: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items), and a further unscaled single item (question 2) for perceived stability or change in health (Health Transition) during the last year. The norm based scores (based on the US general population) were used for analysis. For the MCS, the lowest and highest possible scores are -9 and 82 (rounded). The SF-36 domains (subscores) are scored so that a higher score indicates a better health state.

    Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period

  14. Change From Baseline in the Short-Form-36 (SF-36) Item Questionnaire Physical Component Summary (PCS) to the End of the Maintenance Period

    The SF-36 is a 36 item generic human research quality of life instrument that uses a recall period of 4 weeks. Items are grouped into 8 domains as follows: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items), and a further unscaled single item (question 2) for perceived stability or change in health (Health Transition) during the last year. The norm-based scores (based on the US general population) were used for analysis. For the PCS, the lowest and highest possible scores are 1 and 81 (rounded). The SF-36 domains (subscores) are scored so that a higher score indicates a better health state.

    Time frame: From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period

07

Results

Posted Nov 3, 2014

Participant flow

The recruitment for the SP0934 study began in April 2012. It concluded in October 2013. This was a multicenter study with subjects enrolled by 9 sites across Europe and 6 sites across the United States.

Participant flow — Overall Study
MilestonePlaceboRotigotine
Started1020
Completed1015
Not completed05
Withdrew: Adverse event02
Withdrew: Lack of efficacy01
Withdrew: Protocol violation01
Withdrew: Other01

Outcome measures

PrimaryRatio From Baseline to the End of the 2-week Maintenance Period in Periodic Limb Movement Index (PLMI)

The PLMI is defined as Periodic Limb Movements (PLMs)/ total time in bed in hours. PLMs are measured by Polysomnography (PSG). The reduction of the PLMI is reflected in terms of the ratio from Baseline to the end of the Maintenance Period and was calculated as \[PLMI at end of Maintenance Period (MP)\] / \[PLMI at Baseline\]. A PLMI Ratio \<1 indicates an improvement from Baseline to the end of the 2-week MP.

Time frame:
From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Reported as:
Least squares mean · ratio
Ratio From Baseline to the End of the 2-week Maintenance Period in Periodic Limb Movement Index (PLMI)
ratioPlaceboRotigotine
Ratio From Baseline to the End of the 2-week Maintenance Period in Periodic Limb Movement Index (PLMI)1.16 (0.68 to 1.99)0.51 (0.33 to 0.80)
Statistical analysis
  • Placebo vs Rotigotine · ANCOVA · p = 0.0232 · Treatment ratio: 0.44 · 95% CI 0.22 to 0.88An analysis of covariance (ANCOVA) was performed for the log-transformed PLMI ratio with treatment and region as factors and Baseline as a covariate.
SecondaryChange From Baseline in the Periodic Limb Movements Index (PLMI) to the End of the Maintenance Period

The PLMI is defined as Periodic Limb Movements (PLMs)/ total time in bed in hours. PLMs are measured by Polysomnography (PSG). A negative value in change from Baseline indicates an improvement from Baseline to the end of the Maintenance Period.

Time frame:
From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Reported as:
Mean · movement/ hour
Change From Baseline in the Periodic Limb Movements Index (PLMI) to the End of the Maintenance Period
movement/ hourPlaceboRotigotine
Change From Baseline in the Periodic Limb Movements Index (PLMI) to the End of the Maintenance Period10.3 ± 21-23.7 ± 38.7
SecondaryChange From Baseline in the International Restless Legs Syndrome Study Group Rating Scale (IRLS) Sum Score to the End of the Maintenance Period

The IRLS is a subject based scale that consists of 10 items to evaluate the severity of major RLS symptoms and the impact of the disease on subjects' functioning in daytime activities. Each of the 10 items is measured on a scale that ranges from 0 (not present) to 4 (severe). A sum score between 0 (no RLS symptoms present at all) and 40 (maximum severity in all symptoms) across all 10 items will be calculated. A negative value in Change from Baseline indicates an improvement from Baseline in IRLS.

Time frame:
From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in the International Restless Legs Syndrome Study Group Rating Scale (IRLS) Sum Score to the End of the Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in the International Restless Legs Syndrome Study Group Rating Scale (IRLS) Sum Score to the End of the Maintenance Period-8.6 ± 7.2-15.9 ± 9.1
SecondaryChange From Baseline in Clinical Global Impressions (CGI) Item 1 Score

The CGI Item 1 score measures the severity of illness on a scale that ranges from 0 (Not assessed) to 7 (Among the most extremely ill).

Time frame:
Visit 2 (Baseline); Visit 6 (End of Maintence Period)
Reported as:
Number · participants
Change From Baseline in Clinical Global Impressions (CGI) Item 1 Score
participantsPlacebo (Visit 2)Rotigotine (Visit 2)Placebo (Visit 6)Rotigotine (Visit 6)
Not assessed0000
Normal, not ill at all0015
Borderline ill0014
Mildly ill0033
Moderately ill3351
Markedly ill5902
Severely ill2200
Among the most extremely ill subjects0100
SecondaryChange From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 1 to the End of the Maintenance Period

The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 1 measures satisfaction with sleep during the last seven nights on an 11-point scale that ranges between 0 (completely satisfied) to 10 (completely dissatisfied). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 1 to the End of the Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 1 to the End of the Maintenance Period-1.1 ± 3.5-2.8 ± 3.2
SecondaryChange From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 2 to the End of the Maintenance Period

The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 2 measures the severity of RLS symptoms during the last 7 nights in the situation of falling asleep. This is measured on an 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 2 to the End of the Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 2 to the End of the Maintenance Period-2.8 ± 2.9-4.4 ± 2.9
SecondaryChange From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 3 to the End of the Maintenance Period

The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 3 measures the severity of RLS symptoms during the last seven nights on an 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 3 to the End of the Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 3 to the End of the Maintenance Period-3.2 ± 2.6-4.7 ± 3.1
SecondaryChange From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 4 to the End of the Maintenance Period

The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 4 measures the severity of RLS symptoms during the last seven days at rest on an 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 4 to the End of the Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 4 to the End of the Maintenance Period-1.6 ± 3.2-2.6 ± 2.2
SecondaryChange From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 5 to the End of the Maintenance Period

The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 5 measures the severity of RLS symptoms during the last seven days engaged in activities on an 11-point scale that ranges between 0 (none) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 5 to the End of the Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 5 to the End of the Maintenance Period-1.6 ± 2.1-1.6 ± 2.7
SecondaryChange From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 6 to the End of the Maintenance Period

The RLS-6 consists of six scales of which four scales are designed to assess severity of RLS and two scales cover sleep and daytime tiredness. Scale 6 measures the severity of daytime tiredness/ sleepiness on an 11-point scale that ranges between 0 (not at all) to 10 (very severe). The ratings are given by the subjects. A negative value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 6 to the End of the Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in the Restless Legs-6 (RLS-6) Rating Scale 6 to the End of the Maintenance Period-1.6 ± 2.0-3.4 ± 2.3
SecondaryChange From Baseline in the Periodic Limb Movement During Sleep Arousal Index (PLMSAI) to the End of the Maintenance Period

The Periodic Limb Movement during Sleep Arousal Index (PLMSAI) reflects the influence of the PLM on subject's sleep. Arousal is defined as sudden change in the Electroencephalogram (EEG) activity and the index illustrates to what degree the PLMs contribute to arousal from sleep. A negative value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Reported as:
Mean · movement per hour
Change From Baseline in the Periodic Limb Movement During Sleep Arousal Index (PLMSAI) to the End of the Maintenance Period
movement per hourPlaceboRotigotine
Change From Baseline in the Periodic Limb Movement During Sleep Arousal Index (PLMSAI) to the End of the Maintenance Period4.634 ± 7.162-1.609 ± 14.412
SecondaryChange From Baseline in Sleep Efficiency to the End of the Maintenance Period

Sleep stages and time spent in each sleep stage are determined from Electroencephalogram (EEG) readings. Sleep stage data will be used to calculate sleep efficiency. Sleep efficiency will be presented as percentages. Sleep efficiency is the percentage of time in bed spent asleep. A postive value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Reported as:
Mean · sleep time/ total time in bed
Change From Baseline in Sleep Efficiency to the End of the Maintenance Period
sleep time/ total time in bedPlaceboRotigotine
Change From Baseline in Sleep Efficiency to the End of the Maintenance Period-2.850 ± 10.3477.668 ± 12.317
SecondaryChange From Baseline in the Restless Legs-Quality of Life (RLS-QoL) Total Score to the End of the Maintenance Period

The RLS-QoL is a disease-specific questionnaire to evaluate quality of life. It consists of 12 items. A total score will be calculated from all of the 12 items. The overall sum score can be from 0 (highest QoL) to 60 (lowest QoL). A negative value in Change from Baseline indicates an improvement from Baseline.

Time frame:
From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Reported as:
Mean · scores on a scale
Change From Baseline in the Restless Legs-Quality of Life (RLS-QoL) Total Score to the End of the Maintenance Period
scores on a scalePlaceboRotigotine
Change From Baseline in the Restless Legs-Quality of Life (RLS-QoL) Total Score to the End of the Maintenance Period-10.2 ± 10.8-10.7 ± 10.9
SecondaryChange From Baseline in the Short-Form-36 (SF-36) Item Questionnaire Mental Component Summary (MCS) to the End of the Maintenance Period

The SF-36 is a 36 item generic human research quality of life instrument that uses a recall period of 4 weeks. Items are grouped into 8 domains as follows: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items), and a further unscaled single item (question 2) for perceived stability or change in health (Health Transition) during the last year. The norm based scores (based on the US general population) were used for analysis. For the MCS, the lowest and highest possible scores are -9 and 82 (rounded). The SF-36 domains (subscores) are scored so that a higher score indicates a better health state.

Time frame:
From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in the Short-Form-36 (SF-36) Item Questionnaire Mental Component Summary (MCS) to the End of the Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in the Short-Form-36 (SF-36) Item Questionnaire Mental Component Summary (MCS) to the End of the Maintenance Period6.4 ± 6.62.2 ± 10.1
SecondaryChange From Baseline in the Short-Form-36 (SF-36) Item Questionnaire Physical Component Summary (PCS) to the End of the Maintenance Period

The SF-36 is a 36 item generic human research quality of life instrument that uses a recall period of 4 weeks. Items are grouped into 8 domains as follows: Physical Functioning (10 items), Role Physical (4 items), Bodily Pain (2 items), General Health (5 items), Vitality (4 items), Social Functioning (2 items), Role Emotional (3 items), Mental Health (5 items), and a further unscaled single item (question 2) for perceived stability or change in health (Health Transition) during the last year. The norm-based scores (based on the US general population) were used for analysis. For the PCS, the lowest and highest possible scores are 1 and 81 (rounded). The SF-36 domains (subscores) are scored so that a higher score indicates a better health state.

Time frame:
From Baseline over the Up-Titration Period (up to 3 Weeks) to the end of the 2-Week Maintenance Period
Reported as:
Mean · units on a scale
Change From Baseline in the Short-Form-36 (SF-36) Item Questionnaire Physical Component Summary (PCS) to the End of the Maintenance Period
units on a scalePlaceboRotigotine
Change From Baseline in the Short-Form-36 (SF-36) Item Questionnaire Physical Component Summary (PCS) to the End of the Maintenance Period-0.3 ± 8.73.8 ± 6.3

Adverse events

Collected over Adverse Events were recorded during the course of the SP0934 study, which began in April 2012 and concluded in October 2013.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo—1/10 (10%)4/10 (40%)
Rotigotine—3/20 (15%)12/20 (60%)
Most frequent serious events
Most frequent serious events
EventPlaceboRotigotine
Gastrointestinal infectionInfections and infestations1/100/20
Abdominal painGastrointestinal disorders0/101/20
Chest painGeneral disorders0/101/20
Foot fractureInjury, poisoning and procedural complications0/101/20
AnxietyPsychiatric disorders0/101/20
DyspnoeaRespiratory, thoracic and mediastinal disorders0/101/20
Most frequent other events
Showing 10 of 28
Most frequent other events
EventPlaceboRotigotine
DiarrhoeaGastrointestinal disorders2/101/20
NauseaGastrointestinal disorders0/104/20
VomitingGastrointestinal disorders0/103/20
FatigueGeneral disorders1/100/20
Oedema peripheralGeneral disorders1/100/20
HeadacheNervous system disorders0/102/20
DyspnoeaRespiratory, thoracic and mediastinal disorders0/102/20
HypertensionVascular disorders0/102/20
Eye haemorrhageEye disorders0/101/20
ConstipationGastrointestinal disorders0/101/20

Baseline characteristics

The baseline analysis population consisted of the Safety Set (SS), which is all subjects who were randomized and had at least 1 patch applied during the Treatment Period.

Age, Continuous
Age, Continuous(years)PlaceboRotigotineTotal
Mean50.7 ± 16.357.2 ± 12.655.0 ± 14.0
Age, Categorical
Age, Categorical(Participants)PlaceboRotigotineTotal
<=18 years000
Between 18 and 65 years81523
>=65 years257
Sex: Female, Male
Sex: Female, Male(Participants)PlaceboRotigotineTotal
Female3710
Male71320
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PlaceboRotigotineTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American268
White41317
More than one race101
Unknown or Not Reported314
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PlaceboRotigotineTotal
Hispanic or Latino235
Not Hispanic or Latino51621
Unknown or Not Reported314
Region of Enrollment
Region of Enrollment(participants)PlaceboRotigotineTotal
United States61218
Europe4812
Weight
Weight(Kilograms)PlaceboRotigotineTotal
Mean85.38 ± 20.9989.42 ± 15.3488.07 ± 17.17
Height
Height(Centimeters)PlaceboRotigotineTotal
Mean171.77 ± 8.59171.50 ± 11.99171.59 ± 10.82

1 further baseline measures are reported on the registry.

08

Study locations

15 sites
  • 606
    Brandon, Florida, United States
  • 604
    Newton, Massachusetts, United States
  • 603
    West Seneca, New York, United States
  • 607
    Dublin, Ohio, United States
  • 605
    West Chester, Pennsylvania, United States
  • 601
    Austin, Texas, United States
  • 101
    Innsbruck, Austria
  • 201
    Helsinki, Finland
  • 203
    Tampere, Finland
  • 302
    Bordeaux, France
  • 301
    Montpellier Cédex 5, France
  • 404
    Berlin, Germany
  • 401
    Marburg, Germany
  • 402
    Schwerin, Germany
  • 502
    Pisa, Italy
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Apr 2012, a primary completion of Oct 2013 and a completion of Oct 2013. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2014, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 16, 2012
First posted
Feb 22, 2012
Start
Apr 2012
Primary completionActual
Oct 2013
CompletionActual
Oct 2013
Results first posted
Nov 3, 2014
Last update
Nov 3, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 3, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01537042
Responsible party
Sponsor
First posted
Feb 22, 2012
Start date
Apr 2012
Primary completion
Oct 2013
Completion
Oct 2013
Results posted
Nov 3, 2014
Last update
Nov 3, 2014

Study contacts

UCB Clinical Trial Call Center
study director · +1 877 822 9493 (UCB)

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Rotigotine

Start the discussion